Advertisement
Advertisement
RVMD
Revolution Medicines, Inc. Common Stock
145.72
USDSponsored
+1.57
+1.09%
May 12, 16:00 UTC -4
Closed
After-Market
146.80
+1.08
+0.74%
RVMD Earnings Reports
Positive Surprise Ratio
RVMD beat 7 of 26 last estimates.
27%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$19.74M
/-$1.95
Implied change from Q1 26 (Revenue/ EPS)
--
/-14.85%
Implied change from Q2 25 (Revenue/ EPS)
--
/+48.85%
Revolution Medicines, Inc. Common Stock earnings per share and revenue
On May 06, 2026, RVMD reported earnings of -2.29 USD per share (EPS) for Q1 26, missing the estimate of -1.87 USD, resulting in a -22.07% surprise. Revenue reached --, compared to an expected 2.47 million, with a -100.00% difference. The market reacted with a -5.67% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 14 analysts forecast an EPS of -1.95 USD, with revenue projected to reach 19.74 million USD, implying an decrease of -14.85% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Olema Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.52
Surprise
+3.60%
Kura Oncology, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.83
Surprise
-28.56%
Arvinas, Inc
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.93
Actual
-$0.90
Surprise
+4.00%
Lineage Cell Therapeutics, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-47.06%
SAB Biotherapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-50.28%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.41
Actual
-$0.33
Surprise
+19.67%
Nkarta, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.38
Actual
-$0.37
Surprise
+2.63%
MaxCyte, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.04
Surprise
+50.98%
TELA Bio, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.19
Actual
-$0.21
Surprise
-9.37%
Imunon, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$1.13
Actual
-$0.84
Surprise
+25.81%
FAQ
What were Revolution Medicines, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Revolution Medicines, Inc. Common Stock reported EPS of -$2.29, missing estimates by -22.07%, and revenue of $0.00, -100% below expectations.
How did the market react to Revolution Medicines, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -5.67%, changed from $151.07 before the earnings release to $142.51 the day after.
When is Revolution Medicines, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Revolution Medicines, Inc. Common Stock's next earnings report?
Based on 14
analysts, Revolution Medicines, Inc. Common Stock is expected to report EPS of -$1.95 and revenue of $19.74M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement